Last reviewed · How we verify
Dupilumab for MAD
At a glance
| Generic name | Dupilumab for MAD |
|---|---|
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dupilumab for MAD CI brief — competitive landscape report
- Dupilumab for MAD updates RSS · CI watch RSS
- Innovent Biologics (Suzhou) Co. Ltd. portfolio CI